A Study to Compare rhuFab V2 With Verteporfin Photodynamic in Treating Subfoveal Neovascular Macular Degeneration
Status:
Completed
Trial end date:
2006-09-01
Target enrollment:
Participant gender:
Summary
This is a phase III, multicenter, randomized, double-masked, active treatment-controlled
study of intravitreally administered ranibizumab compared with verteporfin (Visudyne)
photodynamic therapy (PDT) in treating subfoveal neovascular mascular degeneration.